Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.54 |
| ▸ | METAP1 | P53582 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | SRD5A1 | P18405 | 5/20 | 0.42 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.42 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3847559 | 0.92 | CYP2A6 (0.54) | CYP2A6METAP1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL12430501 | 0.88 | METAP1 (0.44) | CYP2A6METAP1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL10177007 | 0.87 | METAP1 (0.46) | CYP2A6METAP1CYP3A4SRD5A1PARP10 | |
| SCHEMBL4971962 | 0.85 | CYP1A2 (0.56) | CYP2A6METAP1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL6584911 | 0.85 | METAP1 (0.52) | CYP2A6METAP1CYP3A4CYP1A2PARP10 | |
| SCHEMBL27861246 | 0.81 | CYP2A6 (0.46) | CYP2A6METAP1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL27844103 | 0.81 | CYP2A6 (0.46) | CYP2A6METAP1CYP3A4CYP1A2CYP2C9 | |
| SCHEMBL17037968 | 0.80 | METAP1 (0.44) | CYP2A6METAP1CYP3A4SRD5A1PARP10 | |
| SCHEMBL5146565 | 0.80 | METAP1 (0.44) | CYP2A6METAP1CYP3A4PARP10PARP11 | |
| SCHEMBL5929505 | 0.78 | CYP2A6 (0.58) | CYP2A6METAP1CYP3A4CYP1A2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11905248-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2024-02-20 | — | — | US | disclosed |
| US-20230192733-A1 | SUBSTITUTED PHENYL ET458HYNYL PYRIDINE CARBOXAMIDES AS POTENT INHIBITORS OF SARS VIRUS | SOUTHERN RESEARCH INSTITUTE | 2023-06-22 | — | — | US | disclosed |
| US-20200317617-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2020-10-08 | — | — | US | disclosed |
| US-20200317617-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2020-10-08 | — | — | US | disclosed |
| US-10703722-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10703722-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2020-07-07 | — | — | US | disclosed |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-26 | — | — | US | disclosed |
| US-10000450-B2 | N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| US-20180162848-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2018-06-14 | — | — | US | disclosed |
| US-20180072721-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED-3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2018-03-15 | — | — | US | disclosed |
| EP-1140908-A1 | TRIAZOLE COMPOUNDS WITH DOPAMINE-D3-RECEPTOR AFFINITY | BASF AKTIENGESELLSCHAFT (DE) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000042038-A1 | TRIAZOLE COMPOUNDS WITH DOPAMINE-D3-RECEPTOR AFFINITY | BASF AKTIENGESELLSCHAFT (DE) | 2000-07-20 | — | — | WO | disclosed |
| EP-0343830-B1 | Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes | LILLY CO ELI (US) | 1994-07-13 | — | — | EP | disclosed |
| CN-1024665-C | process for preparing ring-substituted 2-amino-1, 2, 3, 4-tetrahydronaphthalenes | LILLY CO ELI (US) | 1994-05-25 | — | — | CN | disclosed |
| EP-0414289-B1 | Spirocyclic antipsychotic agents | MERCK SHARP & DOHME (GB) | 1994-02-23 | — | — | EP | disclosed |
| US-5026707-A | Antiserotonine agents | ELI LILLY AND COMPANY (US) | 1991-06-25 | — | — | US | disclosed |
| EP-0414289-A1 | Spirocyclic antipsychotic agents | MERCK SHARP & DOHME LTD. (GB) | 1991-02-27 | — | — | EP | disclosed |
| CN-1038644-A | Nuclear substituted 2-amino-1,2,3,4-tetralin class | LILLY CO ELI (US) | 1990-01-10 | — | — | CN | disclosed |
| EP-0103990-A1 | Process for making diarylamines | UNIROYAL, INC. (US) | 1984-03-28 | — | — | EP | disclosed |
| US-4431841-A | REACTING PRIMARY AROMATIC AMINES AND ALICYCLIC KETONES USING AN ACID PROMOTER AND A PLATINUM CATALYST | UNIROYAL, INC. (US) | 1984-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162848-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | CYP2A6 2674/4885METAP1 3367/4885CYP3A4 3595/4885 |
| US-10703722-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | CYP2A6 4078/4885METAP1 3884/4885CYP3A4 4329/4885 |
| US-10000450-B2 | N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | SLC6A2, TPH1, SLC6A3 | CYP2A6 565/4885METAP1 206/4885CYP3A4 380/4885 |
| US-20230192733-A1 | SUBSTITUTED PHENYL ET458HYNYL PYRIDINE CARBOXAMIDES AS POTENT INHIBITORS OF SARS VIRUS | SARS1, ACE2, ACE | CYP2A6 2133/4885METAP1 1341/4885CYP3A4 106/4885 |
| US-20180072721-A1 | NOVEL 3,5-DISUBSTITUTED-3H-IMIDAZO[4,5-B]PYRIDINE AND 3,5-DISUBSTITUTED-3H-[1,2,3]TRIAZOLO[4,5-B] PYRIDINE COMPOUNDS AS MODULATORS OF C-MET PROTEIN KINASES | MET, PRKCH, PRKCE | CYP2A6 4326/4885METAP1 999/4885CYP3A4 3736/4885 |
| US-20200317617-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | CYP2A6 4078/4885METAP1 3884/4885CYP3A4 4329/4885 |
| US-10005767-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | CYP2A6 3282/4885METAP1 3500/4885CYP3A4 3814/4885 |
| US-11905248-B2 | Compounds that modulate intracellular calcium | ORAI1, SARAF, RYR2 | CYP2A6 4078/4885METAP1 3884/4885CYP3A4 4329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.